- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07488832
Infusão Intravenosa de Lidocaína em Cirurgia de Fusão Lombar
Efeito da Infusão Intravenosa Intraoperatória de Lidocaína no Consumo Pós-operatório de Opioides e na Recuperação Após Cirurgia de Fusão Lombar: Um Ensaio Controlado Randomizado
Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.
This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Lumbar fusion surgery is frequently associated with significant postoperative pain and often requires high doses of opioid analgesics during the perioperative period. Opioid administration may lead to several adverse effects including postoperative nausea and vomiting, sedation, respiratory depression, and delayed recovery. Therefore, multimodal analgesia strategies are increasingly used to improve postoperative pain control and reduce opioid requirements.
Intravenous lidocaine infusion has gained attention as an adjunct component of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties. Previous clinical studies have suggested that perioperative systemic lidocaine may reduce postoperative pain intensity, decrease opioid consumption, and improve recovery after surgery. However, evidence regarding its effectiveness in patients undergoing lumbar fusion surgery remains limited.
This prospective, randomized, placebo-controlled study will include adult patients aged 18 years or older with American Society of Anesthesiologists (ASA) physical status I-III who are scheduled for elective lumbar fusion surgery. Participants will be randomly allocated into two groups. Patients in the lidocaine group will receive an intravenous lidocaine bolus followed by continuous lidocaine infusion during surgery, whereas patients in the control group will receive an equivalent volume of normal saline infusion. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.
All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Postoperative pain will be assessed using the Numerical Rating Scale (NRS). Rescue analgesia will be administered when clinically indicated.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores at predefined time points, time to first rescue analgesic requirement, postoperative nausea and vomiting incidence, quality of recovery measured by QoR-15, post-anesthesia care unit length of stay, time to mobilization, and hospital length of stay.
In addition, inflammatory and oxidative stress responses associated with surgery and lidocaine administration will be evaluated. Blood samples will be collected preoperatively and at 6 and 24 hours postoperatively to measure interleukin-6 (IL-6) levels and markers of thiol-disulfide homeostasis.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Ankara Bilkent City Hospital
- Número de telefone: +90 312 552 6000
- E-mail: ankarasehir@saglik.gov.tr
Locais de estudo
-
-
-
Ankara, Turquia (Türkiye)
- Recrutamento
- Ankara Bilkent City Hospital
-
Contato:
- Gokhan Erdem, MD, PhD
- Número de telefone: 05326258766
- E-mail: drgokhanerdem@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age ≥18 years
- Scheduled for elective lumbar fusion surgery under general anesthesia
- American Society of Anesthesiologists (ASA) physical status I-III
- Ability to provide written informed consent
Exclusion Criteria:
- Refusal to participate in the study
- ASA physical status ≥IV
- Body mass index >35 kg/m²
- Known allergy or hypersensitivity to lidocaine or study medications
- Severe cardiac, hepatic, or renal disease
- Pregnancy
- Neurological disorders affecting pain assessment
- Chronic opioid use
- Use of opioids or antiemetic drugs before surgery
- Inability to cooperate with postoperative assessments
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Lidocaine Infusion
Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg/kg/h throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg/kg/h following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
|
Comparador de Placebo: Placebo (Normal Saline)
Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. |
An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cumulative postoperative opioid consumption within the first 24 hours after surgery
Prazo: 0 to 24 hours after surgery
|
Cumulative opioid consumption during the first 24 postoperative hours will be evaluated. Rescue analgesia will be administered as intravenous tramadol (100 mg) when the Numerical Rating Scale (NRS) pain score is ≥4. The cumulative tramadol dose administered during this period will be recorded in milligrams (mg). |
0 to 24 hours after surgery
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Intraoperative remifentanil consumption
Prazo: From induction of anesthesia to the end of surgery
|
Cumulative remifentanil consumption during surgery will be recorded in micrograms (µg). |
From induction of anesthesia to the end of surgery
|
|
Postoperative pain intensity
Prazo: At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
Postoperative pain intensity will be assessed using the Numerical Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain). |
At arrival in the post-anesthesia care unit and at 2, 4, 6, 12, and 24 hours after surgery
|
|
Time to first rescue analgesic requirement
Prazo: Within the first 24 hours after surgery
|
Time from the end of surgery to the first administration of rescue intravenous tramadol will be recorded. |
Within the first 24 hours after surgery
|
|
Quality of recovery
Prazo: Preoperative baseline and 24 hours after surgery
|
Quality of recovery will be evaluated using the Quality of Recovery-15 (QoR-15) questionnaire, a validated patient-reported outcome measure assessing postoperative recovery. The total score ranges from 0 to 150, with higher scores indicating better postoperative recovery. |
Preoperative baseline and 24 hours after surgery
|
|
Postoperative nausea and vomiting incidence
Prazo: 0-24 hours after surgery
|
The incidence of postoperative nausea and/or vomiting and the requirement for rescue antiemetic treatment will be recorded. |
0-24 hours after surgery
|
|
Post-anesthesia care unit length of stay
Prazo: Immediate postoperative period (up to 24 hours after surgery)
|
Duration of stay in the post-anesthesia care unit will be recorded in minutes. |
Immediate postoperative period (up to 24 hours after surgery)
|
|
Time to mobilization
Prazo: Up to 24 hours after surgery
|
Time from the end of surgery to the first mobilization will be recorded. |
Up to 24 hours after surgery
|
|
Serum interleukin-6 (IL-6) levels
Prazo: Preoperatively and at 6 and 24 hours after surgery
|
Serum interleukin-6 (IL-6) levels will be measured to evaluate the inflammatory response. |
Preoperatively and at 6 and 24 hours after surgery
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Thiol-disulfide homeostasis parameters
Prazo: Preoperatively and at 6 and 24 hours after surgery
|
Native thiol, total thiol, and disulfide levels will be measured to evaluate oxidative stress and thiol-disulfide homeostasis. |
Preoperatively and at 6 and 24 hours after surgery
|
|
Length of hospital stay
Prazo: Through hospital discharge, an average of 5 days
|
Total duration of hospitalization will be recorded in days. |
Through hospital discharge, an average of 5 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Gokhan Erdem, MD, PhD, Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Dor
- Manifestações Neurológicas
- Complicações pós-operatórias
- Processos Patológicos
- Condições Patológicas, Sinais e Sintomas
- Sinais e sintomas
- Dor, Pós-operatório
- Produtos químicos orgânicos
- Preparações farmacêuticas
- Anilides
- Amidas
- Compostos de anilina
- Aminas
- Acetanilidas
- Soluções cristalóides
- Soluções isotônicas
- Soluções
- Lidocaína
- Solução salina
Outros números de identificação do estudo
- LidocaineInfusion
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
No plan to share individual participant data.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .